Jump to content

Nanobio HSV-2 Vaccine Gets 2-Year Grant for Further Testing


Evaluate

Recommended Posts

Haven't heard much of this vaccine until recently.  As far as I know, this is a prophylactic vaccine.  Nice to see them get some funding.

More about the vaccine http://www.nanobio.com/vaccine-pipeline/hsv-2-vaccine/

Link to news article http://www.prnewswire.com/news-releases/nanobio-receives-sbir-grant-for-genital-herpes-vaccine-300418367.html

Quote

ANN ARBOR, Mich., March 6, 2017 /PRNewswire/ -- NanoBio Corporation today announced that it has been awarded a two-year Phase II Small Business Research Innovation (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of an intranasal nanoemulsion (NE) adjuvanted vaccine for the prevention of genital herpes. The grant will fund up to $1.5 million of critical preclinical research and process development activities, including the completion of a pre-IND meeting with the U.S. Food and Drug Administration.

Genital herpes is a sexually transmitted disease most commonly caused by the herpes simplex virus-2 (HSV-2). Infections are lifelong and are often asymptomatic facilitating the spread of the disease amongst sexual partners and from mother to child during birth. Genital herpes is also associated with an increased risk of HIV acquisition. The disease is widespread in both developed and underdeveloped countries, and is a global health priority. According to estimates from the Centers for Disease Control and Prevention (CDC), over 24 million people in the United States are infected with HSV-2 and there are 776,000 new infections each year. Approximately one out of every six people aged 14 to 49 years has an HSV-2 infection. Currently, there are no approved vaccines to prevent or treat the disease.

Under NIAID's suite of preclinical services, researchers at the Cincinnati Children's Hospital Medical Center previously tested NanoBio's intranasal vaccine in several guinea pig challenge studies. "NanoBio's intranasal vaccine is one of the only vaccine candidates we've studied that has shown efficacy in both the prophylactic and the therapeutic animal models," said Dr. David I. Bernstein, Professor of Pediatrics at Cincinnati Children's Hospital Medical Center. "Based on our data with this unique approach, we look forward to seeing the intranasal NE vaccine progress to human clinical studies."

In the prophylactic guinea pig study, the intranasal NE HSV-2 vaccine prevented infection and viral latency in 92 percent of animals vaccinated, versus 8 percent in a no treatment arm. In a separate therapeutic study, animals with recurrent HSV-2 infection were vaccinated with the intranasal NE vaccine. During the post-vaccination observation period, the NE HSV2 vaccine reduced recurrent lesions and viral shedding by more than 50 percent as compared to animals that received no treatment. No adverse events were observed in any of the animals that received the NE vaccine.

"The Phase II SBIR grant is a testament to the potential of NanoBio's intranasal NE vaccine for genital herpes. The funding enables the next step in the development research process," said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. "Throughout the past several years, we have consistently observed that our intranasal vaccine elicits both a serum and a mucosal immune response in animals. This differentiates our program from the many intramuscular HSV-2 vaccines in development. NanoBio's intranasal NE vaccine provides protection both systemically and in mucosal tissues at the port of entry for the herpes virus. Based on pre-clinical data to date, we believe this first line of defense is essential to adequately protect against genital herpes."

About NanoBio
Headquartered in Ann Arbor, Michigan, NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The company's NanoStat® vaccine technology employs a novel oil-in-water nanoemulsion (NE) that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal or intramuscular vaccination. When applied intranasally, NE vaccines elicit both mucosal and systemic immunity.

NanoBio is currently developing NE vaccines for several respiratory and sexually transmitted diseases, including RSV, pertussis, pandemic influenza, anthrax, prophylactic and therapeutic HSV-2, and chlamydia.

 

  • Like 2
Link to comment
Share on other sites

  • 3 weeks later...
  • 5 months later...

I have checked their pipeline and it says that there will be only two phases for the vaccine. Is it a mistake or this vaccine will show the results earlier than other candidates ? 

Link to comment
Share on other sites

Hi Nanobio had a cream that should have been out years ago, finished Phase 3 trials (1st 2 phases looked great) and had a licensing agreement with GSK (GlaxoSmith Klein) to be the next generation Abreeva, Kinda died a quiet death after Phase 3 (did not see results published).

So until it is approved by the FDA and being sold, don't hope to much!

Linkt to a 2010 article

http://www.xconomy.com/detroit-ann-arbor/2010/07/15/nanobio-with-glaxo-as-big-partner-sees-market-in-treating-and-maybe-preventing-cold-sores/#

Link to comment
Share on other sites

7 minutes ago, mcmich said:

Hi Nanobio had a cream that should have been out years ago, finished Phase 3 trials (1st 2 phases looked great) and had a licensing agreement with GSK (GlaxoSmith Klein) to be the next generation Abreeva, Kinda died a quiet death after Phase 3 (did not see results published).

So until it is approved by the FDA and being sold, don't hope to much!

Linkt to a 2010 article

http://www.xconomy.com/detroit-ann-arbor/2010/07/15/nanobio-with-glaxo-as-big-partner-sees-market-in-treating-and-maybe-preventing-cold-sores/#

 But this is for hsv1 only !! Maybe that is why they canceled. 

It is sad we dont have anything till now. Even a pain reliefer !! 

Link to comment
Share on other sites

  • 1 month later...
  • 1 month later...

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Donate

    If Honeycomb has helped you, please help us by making a donation so we can provide you with even better features and services.

  • The Hive is Thriving!

    • Total Topics
      71.9k
    • Total Posts
      485.2k
  • Posts

    • FirstTimeUser
      @WilsoInAuswould appreciate your thoughts as have seen you comment quite a bit before!
    • Marlena
      Good morning. My name is Marlena and I come from Poland. Sorry, my English is average. For two years I have been in a relationship with a man, for a year and a half I have been struggling with intimate problems. On average, my intimate condition is getting worse every month. Then I feel itching, redness, swelling around the entrance to the vagina, small blisters (not always). Most often it is only red and swollen, itches and then disappears. This state lasts 3-4 days. I come from a small town, doctors don't know what it is. They say it's 'skin irritation'. They prescribe moisturizing creams with lactic acid, probiotics. It doesn't help. I did a blood test for HSV on my own, which is very expensive in Poland, but it does not separate HSV1 from HSV2. The doctor, when he shows these results, says that it's not herpes, but irritation. I would like to add that in the past I suffered from herpes on the lips, then it was a 'scab'. There has never been a scab in an intimate area. Sometimes there are blisters that last 1-2 days, but not always. So what do high blood test results mean? I would like to add that in Poland people do not talk about the HSV virus. It's just that sometimes someone has it on their lips and that's it. Results translation: IgM HSV 1/2: questionable IgG HSV 1/2: result above the measuring range https://files.fm/f/4cpu7uee4  
    • FirstTimeUser
      This is my first time posting here. Im generally pretty anxious when it comes to anything to do with health conditions etc. For context I have had jock itch and fungal infections previously on my buttcrack. I have had 0 new sexual partners and I am not concerned about my girlfriend cheating at all. 4 days ago my balls began itching and red pretty much all over, as you can see some general flakeyness and what looks to be a lesion I noticed on Monday when I checked them out. My partner and I do get cold sores from time to time so the anxious part of me is concerned this could be herpes, but at the same time could be some sort of fungal infection. My doctor cant see me until tomorrow so I just have to worry until then. There is no pain and nothing on the penis or anywhere else, just general itchiness. Any ideas if this is herpes or not?  
    • Jeremy Spokein
      Yes, but every married person who I found out about that has this waited 6-8 months into the relationship to disclose it. But maybe you're right. If I had told her 6-7 months in, she'd still have Googled it and flipped out, and maybe it would have been harder then. I don't know. I don't see myself going through this level of pain and rejection so easily next time. I really don't. I'm taking the meds. I use protection. It's been almost a decade since I've had it so I'm not worried about shedding or passing it on so easily. British studies confirm that the first 2 years are the most contagious and we're passed that. I'm just over this. I've never been in so much emotional pain in my life.
    • Possiblehypercon11
      @WilsoInAus would really appreciate your input please. Kinda freaking out lol. 
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.